Opus Genetics, Inc.
NASDAQ:IRDBiotechnology
-$0.01 today
- Market cap
- $326.13M
- Beta
- 0.55
- P/E (TTM)
- -33.0
- EPS (TTM)
- -$0.12
Volume 0.75M
Average 0.81M
IRD Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Opus Genetics, Inc.NASDAQ: IRD
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses growth accelerates
Q1 FY2026 operating expenses of $16.51M rose 15.4% year over year, ahead of the -30.2% change in trailing-twelve-month operating expenses. Sequentially, it rose 7.8% from the prior quarter. Over 3 fiscal years it compounded at +34.7% a year.
Context
- Operating expenses amounted to 371.9% of revenue in FY2025, down 292.8 pp from a year earlier.
- Operating expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +15.4% holds above the trailing-twelve-month pace of -30.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 52.8M USD
- Year-over-year change
- -27.7%
- 4-year CAGR
- +22.7%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 52.8M | -27.7% |
| FY2024 | 2024-12-31 | 73.07M | +146.7% |
| FY2023 | 2023-12-31 | 29.61M | +36.9% |
| FY2022 | 2022-12-31 | 21.62M | -7.2% |
| FY2021 | 2021-12-31 | 23.29M | — |
Operating Expenses vs competitors
How IRD compares with its peers on the latest reported figures
- IRD's LTM Mar 2026 operating expenses of $48.98M is the 8th highest of the 10 companies compared; the peer median is $81.48M.
- Its year-over-year change of -30.2% is the 9th highest of 10, against a peer median of -17.6%.
- Operating expenses amounts to 408.8% of revenue for IRD, versus a peer median of 612.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $125.25M | -17.6% | -16.6% | 680.1% | |
| LTM Mar 2026 | $114.57M | -9.5% | +39.9% | — | |
| LTM Mar 2026 | $87.4M | -16.0% | -20.4% | 7620.1% | |
| LTM Mar 2026 | $81.9M | -18.3% | -6.5% | 544.6% | |
| LTM Mar 2026 | $81.48M | -22.1% | -32.1% | — | |
| LTM Mar 2026 | $56.39M | -15.6% | -12.1% | 45.5% | |
| LTM Mar 2026 | $54.01M | -31.7% | -36.0% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $48.98M | -30.2% | +34.7% | 408.8% |
| LTM Mar 2026 | $42.71M | -20.4% | +3.3% | — | |
| LTM Mar 2026 | $32.29M | +72.1% | +29.2% | — | |
| Peer median (excluding IRD) | $81.48M | -17.6% | -12.1% | 612.4% | |
Competitors are the stored peer set for IRD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 589K | 39.85M | 19.05M | 10.99M | 14.2M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 589K | 39.85M | 19.05M | 10.99M | 14.2M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 15.17M | 14.36M | 17.65M | 26.85M | 30.81M |
| Selling, General & Admin | 8.12M | 7.27M | 11.96M | 18.22M | 21.98M |
| Operating Expenses | 23.29M | 21.62M | 29.61M | 73.07M | 52.8M |
| Depreciation & Amortization | 4K | 4K | 6K | 10K | 53K |
| EBITDA | (56.69M) | 18.22M | (9.97M) | (57.52M) | (48.07M) |
| EBITDA Margin | -9624.3% | 45.7% | -52.3% | -523.3% | -338.6% |
| Operating Income | (22.71M) | 18.23M | (10.56M) | (62.07M) | (38.6M) |
| Operating Margin | -3854.8% | 45.7% | -55.5% | -564.7% | -271.9% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 2K | 9K | 1.33M | 0 | 1.47M |
| Other Income / Expenses | (33.99M) | (23K) | 589K | 4.54M | (10.99M) |
| Income Before Tax | (56.69M) | 18.2M | (9.97M) | (57.53M) | (49.59M) |
| Pre-Tax Margin | -9625.3% | 45.7% | -52.4% | -523.4% | -349.3% |
| Income Tax Expense | 0 | 315K | 12K | 0 | 0 |
| Net Income | (56.69M) | 17.89M | (9.99M) | (57.53M) | (49.59M) |
| Net Margin | -9625.3% | 44.9% | -52.4% | -523.4% | -349.3% |
| EPS (Basic) | (3.82) | 0.90 | (0.46) | (2.15) | (0.80) |
| EPS (Diluted) | (3.82) | 0.87 | (0.46) | (2.15) | (0.80) |
| Weighted Avg Shares | 14.85M | 19.93M | 21.59M | 26.72M | 622.22M |
| Weighted Avg Shares (Diluted) | 14.85M | 20.6M | 21.59M | 26.72M | 622.22M |
Opus Genetics, Inc.
NASDAQ:IRD
Intrinsic Alpha fair value
Locked
Current Price
$3.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.